La chaîne d'options affiche les données clés des options sur actions de Catalyst Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Catalyst Pharmaceuticals..

Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock, Chaîne d'Options

CATALYST PHARMACEUTICALS INC

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NYSE">CPRX</a>) short percent of float has risen 5.19% since its last report. The company recently reported that it has 7.73 million shares sold short, which is 8.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.85 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Catalyst Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751050819_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Catalyst Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Catalyst Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Catalyst Pharmaceuticals's peer group average for short interest as a percentage of float is 18.02%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CPRX

Is Catalyst Pharmaceuticals Gaining or Losing Market Support?

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Catalyst Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>)</h3>
<ul class="wp-block-list">
<li>On May 7, Catalyst Pharmaceuticals posted better-than-expected quarterly earnings. &#8220;Catalyst&#8217;s exceptional first quarter performance underscores the continued strength of our commercial strategy and the growing demand for our differentiated therapies,&#8221; said Richard J. Daly, President and CEO of Catalyst. The company's stock fell around 13% over the past month and has a 52-week low of $14.75.</li>
<li>RSI Value: 27.5</li>
<li>CPRX Price Action: Shares of Catalyst Pharmaceuticals fell 2.4% to close at $21.54 on Wednesday.</li>
<li>Edge Stock Ratings: 81.89 Momentum score with Value at 60.40. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/cprx"><img loading="lazy" decoding="async" width="440" height="178" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034459/image-397.png" alt="" class="wp-image-962723" style="width:309px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034459/image-397.png 440w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034459/image-397-300x121.png 300w" sizes="(max-width: 440px) 100vw, 440px" /></a></figure>
<h3 class="wp-block-heading">AVITA Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>)&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 8, Avita Medical reported first-quarter financial results and missed its EPS and sales estimates. &#8220;We&#8217;ve transformed from a single-product, burn-only company into an integrated, multi-product platform positioned to lead in therapeutic acute wound care,&#8221; said Jim Corbett, Chief Executive Officer of AVITA Medical. &#8220;With the February rollout of RECELL GO mini and the nationwide launch of Cohealyx on April 1, our portfolio now addresses a U.S. market opportunity that has expanded from $455 million to more than $3.5 billion.&#8221; The company's stock fell around 21% over the past month and <a href="https://www.benzinga.com/quote/RCEL">has a 52-week low</a> of $4.71.</li>
<li>RSI Value: 24.2</li>
<li>RCEL Price Action: Shares of AVITA Medical fell 3.4% to close at $4.77 on Wednesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626">RCEL stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626"><img loading="lazy" decoding="async" width="922" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034601/image-398.png" alt="" class="wp-image-962725" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034601/image-398.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034601/image-398-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034601/image-398-768x698.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Moleculin Biotech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>)</h3>
<ul class="wp-block-list">
<li>On June 20, Moleculin Biotech announced a $5.9 million public offering of 16,080,000 shares and Series E warrants at $0.37 per share and accompanying warrant. The company's stock fell around 58% over the past five days and has a 52-week<a href="https://www.benzinga.com/quote/MBRX"> low of $0.25.</a></li>
<li>RSI Value: 21.4</li>
<li>MBRX Ltd Price Action: Shares of Moleculin Biotech fell 2.9% to close at $0.29 on Wednesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626">MBRX share</a>s. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0626"><img loading="lazy" decoding="async" width="885" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034652/image-400.png" alt="" class="wp-image-962727" style="width:558px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034652/image-400.png 885w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034652/image-400-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/26034652/image-400-768x726.png 768w" sizes="(max-width: 885px) 100vw, 885px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46093486/top-2-utilities-stocks-that-may-fall-off-a-cliff-in-q2">Top 2 Utilities Stocks That May Fall Off A Cliff In Q2</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

News

Pre-Market Outlook

Markets

MBRX

RCEL

Top 3 Health Care Stocks You'll Regret Missing This Quarter

Revealing a significant insider sell on June 12, Preethi Sundaram, Chief Strategy Officer at Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), as per the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001369568/000116169725000189//Archives/edgar/data/1369568/000116169725000189/0001161697-25-000189-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that Sundaram sold 3,924 shares of Catalyst Pharmaceuticals. The total transaction amounted to $103,648. 
The latest update on Friday morning shows Catalyst Pharmaceuticals shares down by 2.06%, trading at $23.79.
<h3>All You Need to Know About Catalyst Pharmaceuticals</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
<h3>Understanding the Numbers: Catalyst Pharmaceuticals's Finances</h3>
Revenue Growth: Catalyst Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 43.56%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: With a high gross margin of 87.33%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Catalyst Pharmaceuticals's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.47.
</li>
</ul>
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 15.47 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 5.72 is lower than the industry average, implying a discounted valuation for Catalyst Pharmaceuticals's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 8.86, Catalyst Pharmaceuticals's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001369568">Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Preethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals Stock

Revealing a significant insider sell on June 10, Patrick J McEnany, Director at Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), as per the latest SEC filing.
What Happened: McEnany opted to sell 200,000 shares of Catalyst Pharmaceuticals, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001369568/000116169725000185//Archives/edgar/data/1369568/000116169725000185/0001161697-25-000185-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The transaction's total worth stands at $5,217,338.
As of Wednesday morning, Catalyst Pharmaceuticals shares are up by 0.96%, currently priced at $26.56.
<h3>Discovering Catalyst Pharmaceuticals: A Closer Look</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
<h3>Catalyst Pharmaceuticals: A Financial Overview</h3>
Revenue Growth: Catalyst Pharmaceuticals's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 43.56%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 87.33%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Catalyst Pharmaceuticals exhibits below-average bottom-line performance with a current EPS of 0.47.
</li>
</ul>
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 16.76 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 6.19 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 9.78 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Pay Attention to Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Unlocking the Meaning of Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001369568">Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock

WIIM

Catalyst Pharmaceuticals shares are trading lower after the company issued FY25 sales guidance below estimates.

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) affirms FY2025 sales outlook from $545.00 million-$565.00 million to $545.00 million-$565.00 million vs $557.24 million estimate.

Guidance

Catalyst Pharmaceuticals Affirms FY2025 Sales Guidance of $545.00M-$565.00M vs $557.24M Est

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.53 by 28.3 percent. This is a 78.95 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $141.42 million which beat the analyst consensus estimate of $130.86 million by 8.07 percent. This is a 43.56 percent increase over sales of $98.51 million the same period last year.

Earnings

Earnings Beats

Catalyst Pharmaceuticals Q1 Adj. EPS $0.68 Beats $0.53 Estimate, Sales $141.42M Beat $130.86M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Catalyst Pharmaceuticals shares are trading higher after the company announced that Health Canada accepted its AGAMREE new drug submission with priority review.

Biotech

General

Catalyst Pharmaceuticals Announces Health Canada Acceptance Of AGAMREE New Drug Submission With Priority Review For Sub-Licensee Kye Pharmaceuticals

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Diginex Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares surged 108.29%, probably amid an overall rebound after investor uncertainty and several risk factors that led to markets entering correction territory last week.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) shares escalated 25.07%. The company announced that the U.S. Court of Appeals for the D.C. Circuit Court issued a revision to the August 2024 judgment, removing vacatur risk on the Federal Energy Regulatory Commission&#8217;s order.</li>
<li>Celsius Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) stock upped 21.60%, likely reacting to news that PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) is acquiring prebiotic<a href="https://www.benzinga.com//node/44360669" target="_blank" rel="noreferrer noopener"> soda brand Poppi for $1.95 billion</a>.</li>
<li>Signet Jewelers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) stock jumped 21.08% after it reported fourth-quarter FY25 earnings results. Several analysts <a href="https://www.benzinga.com//node/44423649" target="_blank" rel="noreferrer noopener">revised the stock&#8217;s price forecast</a>.</li>
<li>New Fortress Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFE#NASDAQ">NFE</a>) shares escalated 20.63% amid weakness in the dollar after the U.S. launched strikes on Houthi targets. Additionally, strong Chinese economic data could be lifting the demand outlook.</li>
<li>Millrose Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRP#NYSE">MRP</a>) shares jumped 16.61% after the company declared its inaugural dividend <a href="https://www.benzinga.com//node/44365712" target="_blank" rel="noreferrer noopener">and issued a 2025 outlook</a>.</li>
<li>Arcutis Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQT#NASDAQ">ARQT</a>) stock gained 16.35% last week after Health Canada approved its Zoryve cream for treating mild to moderate atopic dermatitis.</li>
<li>Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) stock increased 15.79% after Morgan Stanley upgraded the stock <a href="https://www.benzinga.com//node/44373086" target="_blank" rel="noreferrer noopener">from Underweight to Equal-Weight</a>.</li>
<li>Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) stock upped 15.27%.</li>
<li>StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) shares were up 14.20% after the company reported better-than-expected <a href="https://www.benzinga.com//node/44384778" target="_blank" rel="noreferrer noopener">fourth-quarter EPS and sales</a>.</li>
</ol>
Photo by Around the World Photos on Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44450329/robinhood-roku-and-shopify-are-among-top-10-large-cap-gainers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Robinhood, Roku And Shopify Are Among Top 10 Large-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44450375/xpeng-reddit-and-nucor-are-among-top-10-large-cap-losers-last-week-mar-17-mar-21-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">XPeng, Reddit And Micron Tech Are Among Top 10 Large-Cap Losers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?</a></li>
</ul>

Equities

Mid Cap

Movers

Tech

ARQT

CELH

DGNX

GLNG

LCID

SBSW

STNE

Celsius, Lucid And Signet Are Among Top 10 Mid-Cap Gainers Last Week (Mar 17-Mar 21): Are The Others In Your Portfolio?

Baird analyst Joel Beatty maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Outperform and raises the price target from $28 to $32.

Price Target

Analyst Ratings

Baird Maintains Outperform on Catalyst Pharmaceuticals, Raises Price Target to $32

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $35 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $35 Price Target

Across the recent three months, 4 analysts have shared their insights on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $31.5, a high estimate of $35.00, and a low estimate of $28.00. Witnessing a positive shift, the current average has risen by 1.61% from the previous average price target of $31.00.
<img src="https://www.benzinga.com/files/images/story/2025/1740679219_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Catalyst Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Catalyst Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Catalyst Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Catalyst Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Catalyst Pharmaceuticals's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CPRX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Catalyst Pharmaceuticals analyst ratings.</a>
<h2>About Catalyst Pharmaceuticals</h2>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Catalyst Pharmaceuticals: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 25.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Catalyst Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 34.1%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Catalyst Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of 5.94%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Catalyst Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Stephens &amp; Co. analyst Sudan Loganathan reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Overweight and maintains $33 price target.

Stephens & Co. Reiterates Overweight on Catalyst Pharmaceuticals, Maintains $33 Price Target

Catalyst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.34 by 105.88 percent. This is a 32.08 percent increase over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $141.81 million which beat the analyst consensus estimate of $134.20 million by 5.67 percent. This is a 28.26 percent increase over sales of $110.57 million the same period last year.

Catalyst Pharmaceuticals Q4 2024 Adj EPS $0.70 Beats $0.34 Estimate, Sales $141.81M Beat $134.20M Estimate

AAOI

ABEV

ACMR

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARKO

ASTE

ATEC

AVNS

BATRA

BATRK

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Joel Beatty initiated coverage on Catalyst Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with an Outperform rating and announced a price target of $28. Catalyst Pharmaceuticals shares closed at $22.62 on Monday. <a href="https://www.benzinga.com/quote/CPRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst John Freeman initiated coverage on Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Strong Buy rating and announced a price target of $135. Expand Energy shares closed at $102.87 on Monday. <a href="https://www.benzinga.com/quote/EXE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst John Kim initiated coverage on Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Perform rating and announced a price target of $71. Terreno Realty shares closed at $65.26 on Monday. <a href="https://www.benzinga.com/quote/TRNO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with an Outperform rating and announced a price target of $49. Vera Therapeutics shares closed at $36.54 on Monday. <a href="https://www.benzinga.com/quote/VERA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Oruka Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with an Outperform rating and announced a price target of $20. Oruka Therapeutics shares closed at $13.70 on Monday. <a href="https://www.benzinga.com/quote/ORKA/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock.</a></li>
</ul>
Considering buying EXE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png" alt="" class="wp-image-764898" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Initiation

ORKA

TRNO

VERA

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Press Releases

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy

Health Care

Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update

Management

Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Comments

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (CPRX) Options

Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL